We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Harnessing AI to Improve Drug Combination Design
News

Harnessing AI to Improve Drug Combination Design

Harnessing AI to Improve Drug Combination Design
News

Harnessing AI to Improve Drug Combination Design

Harnessing Artificial Intelligence to Improve Drug Combination Design and Personalized Medicine. Credit: Zac Goh
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Harnessing AI to Improve Drug Combination Design"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine. The auto-commentary builds on a study recently published by the authors in Science Translational Medicine about an artificial intelligence (AI) platform, Quadratic Phenotypic Optimization Platform (QPOP), that substantially improves combination therapy in bortezomib-resistant multiple myeloma to identify the best drug combinations for individual multiple myeloma patients.

It is now evident that complex diseases, such as cancer, often require effective drug combinations to make any significant therapeutic impact. As the drugs in these combination therapies become increasingly specific to molecular targets, designing effective drug combinations as well as choosing the right drug combination for the right patient becomes more difficult.

Artificial intelligence is having a positive impact on drug development and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, QPOP and other small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling. Furthermore, because of the efficiency of the platform, QPOP can also be applied towards precious patient samples to help optimize and personalize combination therapy.

The SLAS Technology auto-commentary, entitled “Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine,” can be accessed for free for a limited time here.

This article has been republished from materials provided by SLAS. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement